New and updated preclinical and clinical data presented by biopharma firms at the American Society of Hematology’s annual meeting, Dec. 5-8, including: Actinium, Allogene, Allovir, Amgen, Amphivena, Apellis, Arch Oncology, Astrazeneca, Attralus, Autolus, Beigene, Bergenbio, Biocryst, Bioniz, Bluebird, BMS, Cellectis, Constellation, Corvus, Crispr, Fate, Fulcrum, Gamida, GBT, Genentech, Gilead, Glycomimetics, IGM, Immunogen, IMV, Intellia, Janssen, Kite, Kura, Lilly, Macrogenics, Magenta, Orca Bio, Poseida, Regeneron, Rhizen, Rocket, Syndax, Syros, Vertex, Viracta.

New and updated preclinical and clinical data presented by biopharma firms at the American Society of Hematology’s annual meeting, Dec. 5-8, including: Company List: Gamida, Glycomimetics, Janssen, Jasper, Kadmon, Keros, Kiadis, Kleo, Maat, Macrogenics, Medigene, Mesoblast, Mustang, Novartis, Oncopeptides, Oncternal, Oryzon, Pfizer, Pharmaessentia, Protagonist, Sangamo, Roche, Rocket, Schrodinger, Seagen, Sierra Oncology, Sumitomo, Sutro, Synthekine, Teneobio, TG, Treadwell, Uniqure, Xencor.